Alzheimer's disease and Down's syndrome: Treating two paths to dementia Review uri icon

Overview

MeSH Major

  • Alzheimer Disease
  • Amyloid beta-Peptides
  • Dementia
  • Down Syndrome

abstract

  • Successful therapy of dementia, like any disease, depends upon understanding its pathogenesis. This review contrasts the dominant pathways to dementia which differ in Alzheimer's disease (AD) and in Down's syndrome (DS). Impaired clearance of neurotoxic amyloid beta peptides (Abeta) leads to dementia in AD. In DS over-production of Abeta plays the dominant role in the development of dementia. It follows, therefore, that the therapy of AD and DS should reflect a different balance between the dominant agent that inhibits the synthesis of Abeta in the brain in AD and increase the clearance of Abeta from the cerebrospinal DS.

publication date

  • April 2013

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.autrev.2012.10.013

PubMed ID

  • 23201920

Additional Document Info

start page

  • 670

end page

  • 3

volume

  • 12

number

  • 6